Product News from the 10/07/05 News Brief

Share this article:

Pfizer received FDA approval to market Aromasin (exemestane tablets) for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following two-to-three years of tamoxifen for a completion of five consecutive years of adjuvant hormonal therapy.

Abbott received FDA approval to market Humira (adalimumab) for first-line treatment of recent onset moderate to severe rheumatoid arthritis (RA). In 2002, Humira was approved to treat patients with moderately to severely active RA, who have had insufficient response to one or more disease-modifying anti-rheumatic drugs (DMARDs).

Berlex, a U.S. affiliate of Schering AG, Germany, announced that the FDA has approved Angeliq (drospirenone and estradiol) to treat moderate to severe vasomotor symptoms associated with menopause. Belex said Angeliq will be the only hormone therapy to contain the unique progestin, drospirenone.

Share this article:

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.